CA2786233C — Anti-inflammatory analgesic adhesive patch for external use
Assigned to IBSA Institut Biochimique SA · Expires 2018-01-02 · 8y expired
What this patent protects
Disclosed is a diclofenac hydroxyethyl pyrrolidine-containing adhesive patch for external use, which is an adhesive patch obtained by arranging an adhesive layer on a supporting body. The diclofenac hydroxyethyl pyrrolidine-containing adhesive patch for external use is characteri…
USPTO Abstract
Disclosed is a diclofenac hydroxyethyl pyrrolidine-containing adhesive patch for external use, which is an adhesive patch obtained by arranging an adhesive layer on a supporting body. The diclofenac hydroxyethyl pyrrolidine-containing adhesive patch for external use is characterized in that the adhesive layer contains, as essential components, 5-50% by weight of a styrene-isoprene-styrene block copolymer, 20-50% by weight of a tackifier resin, 5-70% by weight of a softening agent and 0.5-20% by weight of one or more dissolving agents selected among N-methyl-2-pyrrolidone, propylene glycol and dimethyl sulfoxide, while containing 0.5-20% by weight of diclofenac hydroxyethyl pyrrolidine as an active ingredient. The diclofenac hydroxyethyl pyrrolidine-containing adhesive patch for external use has excellent percutaneous absorption, little skin irritation, and excellent main medicinal ingredient stability.
Drugs covered by this patent
- Saphris (ASENAPINE) · Hisamitsu
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.